-

Kincell Bio Expands Production With New Manufacturing Partner at its Gainesville, FL Facility

New contract reinforces Kincell Bio’s commitment to long-term partnerships to address development and GMP manufacturing support for engineered cellular therapies.

GAINESVILLE, Fla.--(BUSINESS WIRE)--Kincell Bio, a cell therapy-focused cGMP contract development and manufacturing organization (CDMO), today announced that it has welcomed a new client for the production of a cell therapy product to address degenerative disease.

The agreement represents a multi-year partnership to produce patient-specific batches of clinical-grade product at Kincell's site in Gainesville, Florida. The multi-year contract adds to the work for other clients already in progress at the site.

Share

The agreement represents a multi-year partnership to produce patient-specific batches of clinical-grade product at its site in Gainesville, Florida. The multi-year contract adds to the work for other clients already in progress at the site.

“We’re delighted to welcome another client to our Gainesville facility,” said Bruce Thompson, PhD., CEO of Kincell Bio. “Our facility is GMP-ready, and our team thrives on providing critical CMC development and manufacturing expertise to support our clients’ clinical development plans to help patients.”

The client is a clinical stage cell therapy company pursuing regenerative medicine in a variety of critical indications. This project reflects Kincell Bio’s expanding portfolio, reinforcing its position as a strong partner in the cell therapy CDMO space.

About Kincell Bio

Kincell Bio engineers cells into therapies. A technology-forward contract development and manufacturing organization (CDMO), Kincell has facilities in both Gainesville, FL and Durham, NC. Kincell was formed to streamline analytical development, process development, CMC consulting and early-stage through registrational GMP cell therapy manufacturing. For more information, visit www.kincellbio.com.

Contacts

Business & Media Enquiries
Bruce Thompson, PhD
Chief Executive Officer
contactus@kincellbio.com

Industry:

Kincell Bio

Release Versions
English
Hashtags
#CDMO
#ClinicalDevelopment
#KincellBio
#celltherapy
#innovation
#lifesciences
#partnership

Contacts

Business & Media Enquiries
Bruce Thompson, PhD
Chief Executive Officer
contactus@kincellbio.com

Social Media Profiles
Kincell Bio on LinkedIn
More News From Kincell Bio

Kincell Bio Announces Partnership with RegCell to Advance Treg Cell Therapies into Clinical Trials for Autoimmune Diseases

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Kincell Bio, a leading U.S. cell therapy contract development and manufacturing organization (CDMO), today announced a new collaboration with RegCell, a biotechnology company developing first‑in‑class immune tolerance platform based on epigenetically reprogrammed regulatory T cells (Tregs). Under the partnership, Kincell Bio will provide comprehensive CMC development and GMP manufacturing support to accelerate RegCell’s lead Treg program toward cli...

Kincell Bio Advances Key Leaders to Accelerate Innovations for Reliable, High Quality Patient Supply in Cell Therapy Manufacturing

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Kincell Bio, a leading contract development and manufacturing organization (CDMO) in cell therapy, today announced the promotion of three accomplished executives to strengthen its leadership team and advance its mission of delivering life-changing therapies to patients worldwide. Bruce Thompson, PhD, has been promoted to President and Chief Technology Officer, driving technology strategy and innovation to provide technical solutions for clients. As...

Kincell Bio Promotes Industry Veteran Larry Pitcher to Chief Executive Officer to Propel Expansion and Client Impact in Cell Therapy Manufacturing

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Kincell Bio, a leading contract development and manufacturing organization (CDMO) in cell therapy, is pleased to announce the promotion of Lawrence “Larry” Pitcher to Chief Executive Officer, effective immediately. Pitcher succeeds Mark R. Bamforth OBE, who guided the company through a successful phase of growth as CEO and will continue to support the transition in a strategic capacity as Executive Chair of the Board. The year of 2025 has been tran...
Back to Newsroom